Journal article · 2023 · Open access

Access to gene therapy for rare diseases when commercialization is not fit for purpose

Thomas Andrew Fox, Juan Antonio Bueren, Fabio Candotti, Alain Fischer, Alessandro Aiuti, Arjan C. Lankester, The AGORA Initiative, Michael H. Albert, Maria Ester Bernardo, Marina Cavazzana, Stephan R. Ehl, Bénédicte Neven and 6 more

Nature Medicine, 29(3), 518–519 · Published 13 February 2023 · DOI 10.1038/s41591-023-02208-8

Open PDFView at the publisherCite this paper

In brief

“Access to gene therapy for rare diseases when commercialization is not fit for purpose” is a 2023 journal article by Thomas Andrew Fox and 17 co-authors, published in Nature Medicine. OpenAlex counts 58 citations as of 21 November 2026, which puts it in the top 2% of works published in 2023 by citations. It is open access: the full text is free to read at Nature Medicine.

Citations
58
Most cited in
2023 (18)
Field-weighted impact
6.47
References
7
Authors
18

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Fox, T. A., Bueren, J. A., Candotti, F., Fischer, A., Aiuti, A., Lankester, A. C., The AGORA Initiative, Albert, M. H., Bernardo, M. E., Cavazzana, M., Ehl, S. R., Neven, B., Prevot, J., Schambach, A., Sevilla, J., Thrasher, A. J., Wynn, R. F., & Booth, C. (2023). Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nature Medicine, 29(3), 518–519. https://doi.org/10.1038/s41591-023-02208-8

MLA 9

Fox, Thomas Andrew, et al. “Access to gene therapy for rare diseases when commercialization is not fit for purpose.” Nature Medicine, vol. 29, no. 3, 2023, pp. 518–519. https://doi.org/10.1038/s41591-023-02208-8.

Chicago

Fox, Thomas Andrew, Juan Antonio Bueren, Fabio Candotti, Alain Fischer, Alessandro Aiuti, Arjan C. Lankester, The AGORA Initiative, et al. 2023. “Access to gene therapy for rare diseases when commercialization is not fit for purpose.” Nature Medicine 29 (3): 518–519. https://doi.org/10.1038/s41591-023-02208-8.

Harvard

Fox, T. A. et al. (2023) ‘Access to gene therapy for rare diseases when commercialization is not fit for purpose’, Nature Medicine, 29(3), pp. 518–519. doi:10.1038/s41591-023-02208-8.

IEEE

T. A. Fox et al., “Access to gene therapy for rare diseases when commercialization is not fit for purpose,” Nature Medicine, vol. 29, no. 3, pp. 518–519, 2023, doi: 10.1038/s41591-023-02208-8.

BibTeX

@article{fox2023access,
  title     = {{Access to gene therapy for rare diseases when commercialization is not fit for purpose}},
  author    = {Fox, Thomas Andrew and Bueren, Juan Antonio and Candotti, Fabio and Fischer, Alain and Aiuti, Alessandro and Lankester, Arjan C. and The AGORA Initiative and Albert, Michael H. and Bernardo, Maria Ester and Cavazzana, Marina and Ehl, Stephan R. and Neven, Bénédicte and Prevot, Johan and Schambach, Axel and Sevilla, Julián and Thrasher, Adrian James and Wynn, Robert Francis and Booth, Claire},
  journal   = {Nature Medicine},
  year      = {2023},
  volume    = {29},
  number    = {3},
  pages     = {518--519},
  doi       = {10.1038/s41591-023-02208-8},
  url       = {https://doi.org/10.1038/s41591-023-02208-8}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20231818
20241616
20251313
20261111

Its field-weighted citation impact is 6.47: it has been cited 6.47 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research

  • gene therapy
  • rare diseases
  • access to treatment
  • commercialization
  • regulatory approval
  • orphan drugs
  • drug pricing
  • European Medicines Agency

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Fox, T. A., Bueren, J. A., Candotti, F., Fischer, A., Aiuti, A., Lankester, A. C., The AGORA Initiative, Albert, M. H., Bernardo, M. E., Cavazzana, M., Ehl, S. R., Neven, B., Prevot, J., Schambach, A., Sevilla, J., Thrasher, A. J., Wynn, R. F., & Booth, C. (2023). Access to gene therapy for rare diseases when commercialization is not fit for purpose. Nature Medicine, 29(3), 518–519. https://doi.org/10.1038/s41591-023-02208-8

How many times has this paper been cited?

58 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Thomas Andrew Fox, Juan Antonio Bueren, Fabio Candotti, Alain Fischer, Alessandro Aiuti, Arjan C. Lankester, The AGORA Initiative, Michael H. Albert, Maria Ester Bernardo, Marina Cavazzana, Stephan R. Ehl, Bénédicte Neven and 6 more.

What is the DOI of this paper?

10.1038/s41591-023-02208-8, permanently at https://doi.org/10.1038/s41591-023-02208-8. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.